Last updated: July 17, 2026

Application No. 18/252,611

MAGL INHIBITORS

Final Rejection

Filed

May 11, 2023

Priority

Nov 13, 2020 — provisional 63/113,662 +1 more

Examiner

NOLAN, JASON MICHAEL

Art Unit

1623

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

H. Lundbeck A/S

OA Round

2 (Final)

Interview Optional

— -28.0% interview lift. Interview lift (-28.0%) is below the 15.0% threshold. A written response is recommended.

Based on 370 resolved cases, 2023–2026

Examiner Intelligence

NOLAN, JASON MICHAEL View full profile →

Grants 66% — above average

Career Allowance Rate

245 granted / 370 resolved

+6.2% vs TC avg

Minimal -28% lift

Without

With

+-28.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 8m

Avg Prosecution

47 currently pending

Career history

420

Total Applications

across all art units

Statute-Specific Performance

§101

1.9%

-38.1% vs TC avg

§103

35.6%

-4.4% vs TC avg

§102

16.4%

-23.6% vs TC avg

§112

37.0%

-3.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 370 resolved cases

Prosecution Timeline

May 11, 2023

Application Filed

May 03, 2024

Response after Non-Final Action

Sep 10, 2025

Non-Final Rejection mailed

Mar 09, 2026

Response Filed

Apr 15, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/029,227

Patent 12643903

BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE

3y 2m to grant Granted Jun 02, 2026

18/603,896

Patent 12643854

PROCESS FOR PREPARING A CRYSTALLINE FORM OF FLUVASTATIN SODIUM SALT

2y 2m to grant Granted Jun 02, 2026

17/742,172

Patent 12583824

6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

3y 10m to grant Granted Mar 24, 2026

17/923,819

Patent 12570661

Isoform-Specific Aldehyde Dehydrogenase Inhibitors

3y 4m to grant Granted Mar 10, 2026

18/040,831

Patent 12565483

OXOPYRROLIDINE UREA FPR2 AGONISTS

3y 0m to grant Granted Mar 03, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

66%

Grant Probability

38%

With Interview (-28.0%)

2y 8m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 370 resolved cases by this examiner. Grant probability derived from career allowance rate.